Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Unusual Whales
Information from the Phase 2a clinical trial of the drug OD-001 has been approved for oral presentation at the upcoming United European Gastroenterology Week in October.
